Regional Administration of Recombinant Tumour Necrosis Factor- in Cancer, with Special Reference to Melanoma

ISSN： 1173-8804

Source： BioDrugs, Vol.9, Iss.3, 1998-03, pp. : 211-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Side effects of cancer treatment with recombinant human tumour necrosis factor alpha: a new challenge for the intensive care unit

By ZWAVELING J H MARING J K GIRIBES A R J KOOPS H SCHRAFFORDT

Clinical Intensive Care, Vol. 8, Iss. 3, 1997-06 ,pp. : 142-150

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Targeting Tumour Necrosis Factor in the Treatment of Rheumatoid Arthritis

By Pearce G.J. Chikanza I.C.

BioDrugs, Vol. 15, Iss. 3, 2001-03 ,pp. : 139-149

Adis International

Access to resources Recommend Favorite

Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy

By Baughman R.P.

BioDrugs, Vol. 17, Iss. 6, 2003-01 ,pp. : 425-431

Adis International

Access to resources Recommend Favorite

Tumour Necrosis Factor- Blockers in Rheumatoid Arthritis: Review of the Clinical Experience

By Richard-Miceli C. Dougados M.

BioDrugs, Vol. 15, Iss. 4, 2001-04 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

Recent Advances in Anti-Tumour Necrosis Factor (TNF) Therapy in Rheumatoid Arthritis: Focus on the Soluble TNF Receptor p75 Fusion Protein, Etanercept

By Moreland L.W.

BioDrugs, Vol. 11, Iss. 3, 1999-03 ,pp. : 201-210

Adis International

Access to resources Recommend Favorite